ArticlePharmacoEconomics - open2026

Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy.

Joseph Tkacz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.